Stemline files Elzonris marketing application Europe for BPDCN; shares up 2%

|About: Stemline Therapeutics (STML)|By:, SA News Editor

Stemline Therapeutics (STML +2.1%) has filed a marketing application in Europe seeking approval for ELZONRIS (tagraxofusp) for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare type of blood cancer. The CD123-directed cytotoxin has accelerated view status.

Subscribe for full text news in your inbox